CLEVELAND – Research out of the Ireland Cancer Center of University Hospitals Case Medical Center, in collaboration with six integrated health plans that are part of the Cancer Research Network, found that the majority of older women with early stage breast cancer fail to adhere to the standard of treatment – five years of daily oral use of the chemo-prevention drug Tamoxifen. To be published in the February issue of Journal of Clinical Oncology and released earlier this month, Cynthia Owusu, MD, of the Ireland Cancer Center (ICC) and colleagues determined that premature tamoxifen discontinuation is quite common and deserves closer attention.
